BiotechTube

Peramivir

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Dec 1, 2015 → Sep 1, 2018

NCT ID
NCT02635724

About Peramivir

Peramivir is a phase 3 stage product being developed by BioCryst Pharmaceuticals for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT02635724. Target conditions include Influenza.

What happened to similar drugs?

20 of 20 similar drugs in Influenza were approved

Approved (20) Terminated (1) Active (0)
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
✅Trivalent Influenza Virus VaccineAstraZenecaApproved
✅Vaxelis + PedvaxHIBMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02635724Phase 3Completed
NCT02665351Phase 2/3Completed

Competing Products

20 competing products in Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1018 for H5N8ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0